Skip to main content
. 2020 Oct 15;5(20):e141514. doi: 10.1172/jci.insight.141514

Figure 2. Lats1 or Lats2 loss of heterozygosity in H7;Lats1/2mut3 mice is required for schwannoma development.

Figure 2

(A) IHC of LATS1 and LATS2 on schwannoma and sciatic nerve sections from H7;Lats1/2mut3 mice. (B) Diagram of PCR primer design for detecting the WT, Flox, or Δfloxed alleles of Lats1 or Lats2. (C) Gel electrophoresis of DNSC and tumor PCR products. β-Actin was used as an internal control (n = 3–4). Y, Ad-Cre infected; N, no Ad-Cre infected; T, tumors; M, DNA marker. (D) Diagram of experimental design for testing tumor formation potential of E13.5 DNSCs in vivo. (E) Morphology of E13.5 DNSCs (Lats1/2mut) infected with Ad-GFP or Ad-Cre. (F) Left: Gross picture of nude mice injected with E13.5 DNSCs (Lats1/2mut4-Ad-GFP) (left side) or E13.5 DNSCs (Lats1/2mut4-Ad-Cre) (right side, red circles) (n = 4). Right: H&E histology (top) and IHC (bottom) for LATS1 and LATS2 in Lats1/2mut4-Ad-Cre tumor. L1/2mut4, Lats1/2mut4; +Con, positive control; H7, Hoxb7-Cre; L1, Lats1; L2, Lats2. Scale bars: 50 μm.